{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T23:54:16Z","timestamp":1788479656369,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T00:00:00Z","timestamp":1761523200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82273732"],"award-info":[{"award-number":["82273732"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Real World Research Project Grant Fund from the Hainan Institute of Real World Data","award":["HNLC2022RWS018"],"award-info":[{"award-number":["HNLC2022RWS018"]}]},{"name":"2023 Guangzhou Basic and Applied Basic Research Scheme","award":["2023A04J1106"],"award-info":[{"award-number":["2023A04J1106"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med Res Methodol"],"DOI":"10.1186\/s12874-025-02691-2","type":"journal-article","created":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:28:55Z","timestamp":1761564535000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A bayesian dynamic borrowing framework for improving the efficiency of clinical trials"],"prefix":"10.1186","volume":"25","author":[{"given":"Zengyue","family":"Zheng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keer","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengfei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuping","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dingheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shein-Chung","family":"Chow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,27]]},"reference":[{"issue":"1","key":"2691_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1186\/s12874-022-01768-6","volume":"22","author":"F Liu","year":"2022","unstructured":"Liu F, Panagiotakos D. Real-world data: a brief review of the methods, applications, challenges and opportunities. BMC Med Res Methodol. 2022;22(1):287. https:\/\/doi.org\/10.1186\/s12874-022-01768-6.","journal-title":"BMC Med Res Methodol"},{"issue":"22","key":"2691_CR2","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMms1604593","volume":"374","author":"LE Bothwell","year":"2016","unstructured":"Bothwell LE, Greene JA, Podolsky SH, Jones DS. Assessing the gold Standard\u2013Lessons from the history of RCTs. N Engl J Med. 2016;374(22):2175\u201381. https:\/\/doi.org\/10.1056\/NEJMms1604593.","journal-title":"N Engl J Med"},{"issue":"4","key":"2691_CR3","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1002\/cpt.1351","volume":"105","author":"JM Franklin","year":"2019","unstructured":"Franklin JM, Glynn RJ, Martin D, Schneeweiss S. Evaluating the use of nonrandomized Real-World data analyses for regulatory decision making. Clin Pharmacol Ther. 2019;105(4):867\u201377. https:\/\/doi.org\/10.1002\/cpt.1351.","journal-title":"Clin Pharmacol Ther"},{"issue":"18","key":"2691_CR4","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1056\/NEJMp2200089","volume":"386","author":"J Concato","year":"2022","unstructured":"Concato J, Corrigan-Curay J. Real-World Evidence \u2014 Where are we now? N Engl J Med. 2022;386(18):1680\u20132. https:\/\/doi.org\/10.1056\/NEJMp2200089.","journal-title":"N Engl J Med"},{"issue":"9","key":"2691_CR5","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1001\/jama.2018.10136","volume":"320","author":"J Corrigan-Curay","year":"2018","unstructured":"Corrigan-Curay J, Sacks L, Woodcock J. Real-World evidence and Real-World data for evaluating drug safety and effectiveness. JAMA. 2018;320(9):867. https:\/\/doi.org\/10.1001\/jama.2018.10136.","journal-title":"JAMA"},{"issue":"6","key":"2691_CR6","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s43441-020-00170-y","volume":"54","author":"Y Seifu","year":"2020","unstructured":"Seifu Y, Gamalo-Siebers M, Barthel FMS, et al. Real-World evidence utilization in clinical development reflected by US product labeling: statistical review. Ther Innov Regul Sci. 2020;54(6):1436\u201343. https:\/\/doi.org\/10.1007\/s43441-020-00170-y.","journal-title":"Ther Innov Regul Sci"},{"issue":"1","key":"2691_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1158\/1078-0432.CCR-21-2639","volume":"28","author":"B Arondekar","year":"2021","unstructured":"Arondekar B, Duh MS, Bhak RH, et al. Real-World evidence in support of oncology product registration: A systematic review of new drug application and biologics license application approvals from 2015\u20132020. Clin Cancer Res. 2021;28(1):27. https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-2639.","journal-title":"Clin Cancer Res"},{"issue":"4","key":"2691_CR8","doi-asserted-by":"publisher","first-page":"2857","DOI":"10.1111\/biom.13927","volume":"79","author":"P Yang","year":"2023","unstructured":"Yang P, Zhao Y, Nie L, Vallejo J, Yuan Y, SAM. Self-adapting mixture prior to dynamically borrow information from historical data in clinical trials. Biometrics. 2023;79(4):2857\u201368. https:\/\/doi.org\/10.1111\/biom.13927.","journal-title":"Biometrics"},{"issue":"3","key":"2691_CR9","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/0021-9681(76)90044-8","volume":"29","author":"SJ Pocock","year":"1976","unstructured":"Pocock SJ. The combination of randomized and historical controls in clinical trials. J Chronic Dis. 1976;29(3):175\u201388. https:\/\/doi.org\/10.1016\/0021-9681(76)90044-8.","journal-title":"J Chronic Dis"},{"issue":"7","key":"2691_CR10","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1002\/sim.8019","volume":"38","author":"A Banbeta","year":"2019","unstructured":"Banbeta A, van Rosmalen J, Dejardin D, Lesaffre E. Modified power prior with multiple historical trials for binary endpoints. Stat Med. 2019;38(7):1147\u201369. https:\/\/doi.org\/10.1002\/sim.8019.","journal-title":"Stat Med"},{"key":"2691_CR11","doi-asserted-by":"publisher","unstructured":"Hobbs BP, Sargent DJ, Carlin BP. Commensurate Priors for Incorporating Historical Information in Clinical Trials Using General and Generalized Linear Models. Bayesian Anal. 2012;7(3):639\u201374. https:\/\/doi.org\/10.1214\/12-BA722.","DOI":"10.1214\/12-BA722"},{"key":"2691_CR12","doi-asserted-by":"publisher","unstructured":"Chen MH, Ibrahim JG. Power prior distributions for regression models. Stat Sci. 2000;15(1):46\u201360. https:\/\/doi.org\/10.1214\/ss\/1009212673.","DOI":"10.1214\/ss\/1009212673"},{"issue":"5","key":"2691_CR13","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1002\/bimj.201700246","volume":"61","author":"I Gravestock","year":"2019","unstructured":"Gravestock I, Held L. Power priors based on multiple historical studies for binary outcomes. Biom J. 2019;61(5):1201\u201318. https:\/\/doi.org\/10.1002\/bimj.201700246.","journal-title":"Biom J"},{"issue":"3","key":"2691_CR14","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1111\/j.1541-0420.2011.01564.x","volume":"67","author":"BP Hobbs","year":"2011","unstructured":"Hobbs BP, Carlin BP, Mandrekar SJ, Sargent DJ. Hierarchical commensurate and power prior models for adaptive incorporation of historical information in clinical trials. Biometrics. 2011;67(3):1047\u201356. https:\/\/doi.org\/10.1111\/j.1541-0420.2011.01564.x.","journal-title":"Biometrics"},{"issue":"2","key":"2691_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1093\/biostatistics\/kxx031","volume":"19","author":"AM Kaizer","year":"2018","unstructured":"Kaizer AM, Koopmeiners JS, Hobbs BP. Bayesian hierarchical modeling based on multisource exchangeability. Biostatistics. 2018;19(2):169\u201384. https:\/\/doi.org\/10.1093\/biostatistics\/kxx031.","journal-title":"Biostatistics"},{"issue":"1","key":"2691_CR16","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1177\/1740774509356002","volume":"7","author":"B Neuenschwander","year":"2010","unstructured":"Neuenschwander B, Capkun-Niggli G, Branson M, Spiegelhalter DJ. Summarizing historical information on controls in clinical trials. Clin Trials. 2010;7(1):5\u201318. https:\/\/doi.org\/10.1177\/1740774509356002.","journal-title":"Clin Trials"},{"issue":"4","key":"2691_CR17","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/biom.12242","volume":"70","author":"H Schmidli","year":"2014","unstructured":"Schmidli H, Gsteiger S, Roychoudhury S, O\u2019Hagan A, Spiegelhalter D, Neuenschwander B. Robust meta-analytic-predictive priors in clinical trials with historical control information. Biometrics. 2014;70(4):1023\u201332. https:\/\/doi.org\/10.1111\/biom.12242.","journal-title":"Biometrics"},{"issue":"5","key":"2691_CR18","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/pst.2315","volume":"22","author":"H Zhang","year":"2023","unstructured":"Zhang H, Shen Y, Li J, Ye H, Chiang AY. Adaptively leveraging external data with robust meta-analytical-predictive prior using empirical Bayes. Pharm Stat. 2023;22(5):846\u201360. https:\/\/doi.org\/10.1002\/pst.2315.","journal-title":"Pharm Stat"},{"issue":"4","key":"2691_CR19","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1177\/0962280217747310","volume":"28","author":"A Bertsche","year":"2019","unstructured":"Bertsche A, Fleischer F, Beyersmann J, Nehmiz G. Bayesian phase II optimization for time-to-event data based on historical information. Stat Methods Med Res. 2019;28(4):1272\u201389. https:\/\/doi.org\/10.1177\/0962280217747310.","journal-title":"Stat Methods Med Res"},{"issue":"1","key":"2691_CR20","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1002\/pst.2256","volume":"22","author":"Y Qing","year":"2023","unstructured":"Qing Y, Thall PF, Yuan Y. A bayesian piecewise exponential phase II design for monitoring a time-to-event endpoint. Pharm Stat. 2023;22(1):34\u201344. https:\/\/doi.org\/10.1002\/pst.2256.","journal-title":"Pharm Stat"},{"issue":"2","key":"2691_CR21","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1111\/j.2517-6161.1983.tb01251.x","volume":"45","author":"SR Dalal","year":"1983","unstructured":"Dalal SR, Hall WJ. Approximating priors by mixtures of natural conjugate priors. J Royal Stat Soc Ser B: Stat Methodol. 1983;45(2):278\u201386. https:\/\/doi.org\/10.1111\/j.2517-6161.1983.tb01251.x.","journal-title":"J Royal Stat Soc Ser B: Stat Methodol"},{"key":"2691_CR22","doi-asserted-by":"publisher","unstructured":"Gravestock I, Held L; COMBACTE-Net consortium. Adaptive power priors with empirical Bayes for clinical trials. Pharm Stat. 2017;16(5):349\u201360. https:\/\/doi.org\/10.1002\/pst.1814.","DOI":"10.1002\/pst.1814"},{"issue":"4","key":"2691_CR23","doi-asserted-by":"publisher","first-page":"383","DOI":"10.2307\/2982063","volume":"143","author":"GEP Box","year":"1980","unstructured":"Box GEP. Sampling and bayes\u2019 inference in scientific modelling and robustness. J Royal Stat Soc Ser (General). 1980;143(4):383. https:\/\/doi.org\/10.2307\/2982063.","journal-title":"J Royal Stat Soc Ser (General)"},{"issue":"2","key":"2691_CR24","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1111\/j.1541-0420.2007.00888.x","volume":"64","author":"S Morita","year":"2008","unstructured":"Morita S, Thall PF, M\u00fcller P. Determining the effective sample size of a parametric prior. Biometrics. 2008;64(2):595\u2013602. https:\/\/doi.org\/10.1111\/j.1541-0420.2007.00888.x.","journal-title":"Biometrics"},{"issue":"2","key":"2691_CR25","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1111\/biom.13252","volume":"76","author":"B Neuenschwander","year":"2020","unstructured":"Neuenschwander B, Weber S, Schmidli H, O\u2019Hagan A. Predictively consistent prior effective sample sizes. Biometrics. 2020;76(2):578\u201387. https:\/\/doi.org\/10.1111\/biom.13252.","journal-title":"Biometrics"},{"issue":"3","key":"2691_CR26","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/s41573-023-00638-0","volume":"22","author":"SJ Ruberg","year":"2023","unstructured":"Ruberg SJ, Beckers F, Hemmings R, et al. Application of bayesian approaches in drug development: starting a virtuous cycle. Nat Rev Drug Discov. 2023;22(3):235\u201350. https:\/\/doi.org\/10.1038\/s41573-023-00638-0.","journal-title":"Nat Rev Drug Discov"},{"issue":"7","key":"2691_CR27","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.3324\/haematol.2023.284325","volume":"109","author":"PG Richardson","year":"2024","unstructured":"Richardson PG, Perrot A, Miguel JS, et al. Isatuximab-pomalidomide-dexamethasone versus pomalidomide-dexamethasone in patients with relapsed and refractory multiple myeloma: final overall survival analysis. Haematologica. 2024;109(7):2239\u201349. https:\/\/doi.org\/10.3324\/haematol.2023.284325.","journal-title":"Haematologica"},{"issue":"10214","key":"2691_CR28","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1016\/S0140-6736(19)32556-5","volume":"394","author":"M Attal","year":"2019","unstructured":"Attal M, Richardson PG, Rajkumar SV, et al. Isatuximab plus Pomalidomide and low-dose dexamethasone versus Pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study. Lancet. 2019;394(10214):2096\u2013107. https:\/\/doi.org\/10.1016\/S0140-6736(19)32556-5.","journal-title":"Lancet"},{"issue":"9","key":"2691_CR29","doi-asserted-by":"publisher","first-page":"e7232","DOI":"10.1002\/cam4.7232","volume":"13","author":"X Han","year":"2024","unstructured":"Han X, Jiang X, He J, et al. Clinical outcomes of pomalidomide-based and daratumumab\u2010based therapies in patients with relapsed\/refractory multiple myeloma: A real\u2010world cohort study in China. Cancer Med. 2024;13(9):e7232. https:\/\/doi.org\/10.1002\/cam4.7232.","journal-title":"Cancer Med"},{"issue":"1","key":"2691_CR30","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1186\/s12885-022-09802-y","volume":"22","author":"WJ Fu","year":"2022","unstructured":"Fu WJ, Wang YF, Zhao HG, et al. Efficacy and safety of Pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: a multicenter, prospective, single-arm, phase 2 trial. BMC Cancer. 2022;22(1):722. https:\/\/doi.org\/10.1186\/s12885-022-09802-y.","journal-title":"BMC Cancer"},{"issue":"3","key":"2691_CR31","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1081\/bip-120014564","volume":"12","author":"Jpei Liu","year":"2002","unstructured":"Liu Jpei, Chow SC. Bridging studies in clinical development. J Biopharm Stat. 2002;12(3):359\u201367. https:\/\/doi.org\/10.1081\/bip-120014564.","journal-title":"J Biopharm Stat"},{"key":"2691_CR32","unstructured":"General Principles for Planning and Design of Multi-Regional Clinical Trials, E17. https:\/\/ich.org\/page\/efficacy-guidelines"},{"issue":"8","key":"2691_CR33","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1001\/jama.2017.9991","volume":"318","author":"JP Jarow","year":"2017","unstructured":"Jarow JP, LaVange L, Woodcock J. Multidimensional evidence generation and FDA regulatory decision making: defining and using Real-World data. JAMA. 2017;318(8):703\u20134. https:\/\/doi.org\/10.1001\/jama.2017.9991.","journal-title":"JAMA"}],"container-title":["BMC Medical Research Methodology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12874-025-02691-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12874-025-02691-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:12:34Z","timestamp":1761847954000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedresmethodol.biomedcentral.com\/articles\/10.1186\/s12874-025-02691-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,27]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2691"],"URL":"https:\/\/doi.org\/10.1186\/s12874-025-02691-2","relation":{},"ISSN":["1471-2288"],"issn-type":[{"value":"1471-2288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,27]]},"assertion":[{"value":"26 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and Consent to Participate declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"241"}}